Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muzaffar H Qazilbash

Showing results (31-40 of 188) with videos related to

Pageof 19
Sort By:
Cancer|November 17, 2011
Durable remission with salvage second autotransplants in patients with multiple myelomaNina Shah, Fraz Ahmed, Qaiser Bashir, et al.
European Journal of Haematology|November 19, 2016
Predictors of inferior clinical outcome in patients with standard-risk multiple myelomaTalha Badar, Samer Srour, Qaiser Bashir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2017
Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin LymphomaSai Ravi Pingali, Rima M Saliba, Paolo Anderlini, et al.
British Journal of Haematology|May 10, 2006
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myelomaChitra Hosing, Muzaffar H Qazilbash, Partow Kebriaei, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2026
Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma PatientsChristen M Dillard, Ashwath Gurumurthi, Hans C Lee, et al.
Archives of Pathology & Laboratory Medicine|May 1, 2013
Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasmsGary Lu, Ramya Muddasani, Robert Z Orlowski, et al.
Transfusion|February 11, 2017
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphomaIsabell Ge, Rima M Saliba, Farzaneh Maadani, et al.
Experimental Hematology|May 8, 2013
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implicationsBenigno C Valdez, Guiyun Wang, David Murray, et al.
Leukemia & Lymphoma|October 14, 2010
Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemiaPaolo Anderlini, Sandra A Acholonu, Grace-Julia Okoroji, et al.
Cancers|December 10, 2021
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell NeoplasmC Cameron Yin, Naveen Pemmaraju, M James You, et al.
Pageof 19

Showing results (31-40 of 188) with videos related to

Sort By:
Pageof 19
Cancer|November 17, 2011
Durable remission with salvage second autotransplants in patients with multiple myelomaNina Shah, Fraz Ahmed, Qaiser Bashir, et al.
European Journal of Haematology|November 19, 2016
Predictors of inferior clinical outcome in patients with standard-risk multiple myelomaTalha Badar, Samer Srour, Qaiser Bashir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2017
Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin LymphomaSai Ravi Pingali, Rima M Saliba, Paolo Anderlini, et al.
British Journal of Haematology|May 10, 2006
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myelomaChitra Hosing, Muzaffar H Qazilbash, Partow Kebriaei, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2026
Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma PatientsChristen M Dillard, Ashwath Gurumurthi, Hans C Lee, et al.
Archives of Pathology & Laboratory Medicine|May 1, 2013
Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasmsGary Lu, Ramya Muddasani, Robert Z Orlowski, et al.
Transfusion|February 11, 2017
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphomaIsabell Ge, Rima M Saliba, Farzaneh Maadani, et al.
Experimental Hematology|May 8, 2013
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implicationsBenigno C Valdez, Guiyun Wang, David Murray, et al.
Leukemia & Lymphoma|October 14, 2010
Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemiaPaolo Anderlini, Sandra A Acholonu, Grace-Julia Okoroji, et al.
Cancers|December 10, 2021
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell NeoplasmC Cameron Yin, Naveen Pemmaraju, M James You, et al.
Pageof 19